Back to Journals » Biologics: Targets and Therapy » Volume 1 » Issue 2

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

       
Total article views   HTML views PDF downloads Totals
5,395 Dovepress* 5,395+ 2,142 7,537
Totals 5,395 2,142 7,537
*Since 15 November 2007
+Since July 2016

View citations on Google Scholar